Related Experiment Video
Updated: Apr 24, 2026
23:06
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
Published on: August 11, 2008
18.4K
Delamanid: A new armor in combating drug-resistant tuberculosis
Alphienes Stanley Xavier1, Mageshwaran Lakshmanan1
1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India.
Journal of Pharmacology & Pharmacotherapeutics
|September 12, 2014
Summary
Delamanid is a novel anti-tuberculosis drug targeting mycobacterial cell wall synthesis. It shows high potency and tolerability, with minimal drug-drug interaction risks, offering a new option for multidrug-resistant tuberculosis (MDR-TB) treatment.
Area of Science:
- Pharmacology
- Microbiology
- Infectious Diseases
Background:
- Intensified research for novel anti-tuberculosis (TB) drugs is crucial due to drug resistance, HIV co-infection, and drug-drug interaction risks.
- Multidrug-resistant tuberculosis (MDR-TB) presents a significant global health challenge requiring innovative therapeutic strategies.
Purpose of the Study:
- To evaluate Delamanid, a new inhibitor of mycobacterial cell wall synthesis, as a potential treatment for MDR-TB.
- To assess the efficacy, safety, and tolerability profile of Delamanid in TB management.
Main Methods:
- Preclinical studies investigating the mechanism of action and in vitro activity.
- Clinical trials assessing the safety, tolerability, and efficacy of Delamanid in patients with MDR-TB.
Main Results:
- Delamanid demonstrated high potency against Mycobacterium tuberculosis.
- Preclinical and clinical data indicate a favorable tolerability profile for Delamanid.
- The drug exhibits a low risk of drug-drug interactions, a critical factor in managing complex TB cases.
Conclusions:
- Delamanid is a promising new agent for the treatment of multidrug-resistant tuberculosis (MDR-TB).
- Conditional approval by the European Medicines Agency (EMA) highlights its therapeutic potential.
- Its favorable safety and interaction profile makes it a valuable addition to the TB treatment armamentarium.
Related Concept Videos
01:28Pulmonary Tuberculosis V
972
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
972
01:26Pulmonary Tuberculosis IV
797
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
797
01:16Therapeutic Drug Monitoring: Overview and Classification
622
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
622
01:15Anthelminthic Agents
97
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
97
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
339
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
339
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
739
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
739